Pharmacoeconomic impact of non-compliance with statins.

Abstract

There are numerous studies examining the pharmacoeconomic impact of HMG-CoA reductase inhibitor (statin) therapy on healthcare costs and outcomes. A recently published review demonstrated that the cost-benefit of these agents depends primarily on the risk of developing a coronary event. That is, as the risk of a coronary event increases, the cost… (More)

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.